Newsletter | October 8, 2024

10.08.24 -- Great siRNA Science Or Savvy Business Acumen? You Need Both

FEATURED EDITORIAL

Great siRNA Science Or Savvy Business Acumen? You Need Both

Silence Therapeutics has two wholly owned siRNA therapies now in clinical trials and one partnered program with AstraZeneca. Silence's CEO discusses the need for good science, making smart business decisions, and cultivating partnerships.

INDUSTRY INSIGHTS

Precision Powder-In-Capsule Micro-Dosing Accelerates Drug Development

Precision powder microdosing makes it possible to quickly get formulations to the clinic, saving time, money, and use of limited APIs.

Rapid Development Of Amorphous Solid Dispersions For Bioavailability

See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

Outsourcing Stability Storage: A Cost-Effective Approach

Partnering with a leader in outsourced stability storage is revolutionizing the pharmaceutical and medical device industry to ensure product quality and compliance. 

The Crucial Role Of Downstream Processing In RNA-LNP Drug Development

Explore the key aspects of lipid nanoparticle (LNP) development, including the essential downstream processes of Tangential Flow Filtration (TFF) and normal flow filtration.

An Introduction To Organ-On-A-Chip Technology

Discover how Organ-on-a-Chip technology revolutionizes drug development, overcoming the limitations of traditional models to create more accurate, efficient pathways to life-saving treatments.

Bispecific Antibodies Unleashed

Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

MOST POPULAR NEWS

Team Science Leads To Antimalarial Drug Discovery

Seeing Double: Designing Drugs That Target 'Twin' Cancer Proteins

Japan Tobacco Inc. & D-Wave Collaborate To Accelerate Drug Discovery With Quantum AI

Astria Therapeutics Receives FDA ODD For Navenibart (STAR-0215)

Adnexus Biotechnologies Unveils Sutra

Potential Target For Cataract Drug Development

Papillon Therapeutics Receives ODD From The U.S. FDA For PPL-002

CellarisBio Delivers Real-Time Cell Target Engagement System For Challenging Drug Targets

CAMP4 Enters Strategic Research Collaboration With BioMarin Pharmaceutical Inc.

VeriSIM Life Announces Collaboration With Mayo Clinic To Accelerate New Drug Development

Charles River & Lundbeck Enter Agreement Utilizing Logica To Advance Critical Brain Disease Research

SOLUTIONS

Expediting Drug Discovery From Concept To Commercialization

The Fast Track To IND

Chromatography Modeling Software Solution